Amgen Reports Impressive Third Quarter 2026 Financial Growth and Future Strategies

Amgen's Third Quarter 2026 Financial Highlights

Amgen, a global leader in biotechnology and innovative medicines, has recently announced its financial performance for the third quarter of 2026. As the company continues to execute its long-term growth strategy, the results reflect encouraging progress across multiple sectors of its operations.

CEO Robert A. Bradway expressed confidence in the company’s robust performance, stating, "Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise." He emphasized the strength of Amgen’s commercial portfolio and the significant advances in clinical development, which contribute to the promising outlook for sustained growth well into the next decade.

Financial Results Overview

In the third quarter of 2026, Amgen reported total revenues of approximately $10.4 billion, which marks an increase of 8% compared to the same period in 2025. This growth can be attributed primarily to an 8% rise in product sales driven by increased volume across a variety of therapies. Notably, seventeen Amgen products reported double-digit growth in sales, signaling strong demand and market performance. Furthermore, these products are forecasted to exceed $1 billion in annual sales based on their third-quarter results.

The company’s earnings per share (EPS) showed remarkable growth as well, with GAAP EPS increasing by 19% to reach $7.08, largely due to increased revenues. Non-GAAP EPS followed suit, rising 14% to $6.45, highlighting improved operational performance net of certain expenses.

Operational Highlights

Amgen’s operating income for the third quarter surged from $2.5 billion to $3.7 billion, with an expanded operating margin from 27.6% to 37.5%. The company generated $3.7 billion in free cash flow, which, although slightly down from $4.2 billion in the previous year, remains robust.

Product Sales Performance

Key product sales illustrate the strength of Amgen’s portfolio in various therapeutic areas:
1. General Medicine:
- Repatha® (evolocumab) sales soared by 37% to $1.085 billion.
- EVENITY® (romosozumab-aqqg) saw a 39% increase to $751 million.
- Conversely, Prolia® (denosumab) experienced a notable decline of 45% to $632 million due in part to competition from biosimilars.

2. Rare Diseases:
- UPLIZNA® (inebilizumab-cdon) experienced remarkable growth, with sales surging 191% to $451 million.
- TEPEZZA® (teprotumumab-trbw) saw a slight decrease of 6%, contributing $526 million in sales.

3. Inflammation and Oncology:
- New therapies such as TEZSPIRE® (tezepelumab-ekko) and BLINCYTO® (blinatumomab) also demonstrated strong year-over-year growth, affirming Amgen's leading position in advancing innovative therapeutics.

Looking Ahead

The company anticipates total revenues between $38.9 billion and $39.7 billion for 2026, signaling sustained growth. Amgen is also poised to increase capital expenditures to approximately $2.6 billion and plans share repurchases up to $3 billion, reflecting its commitment to returning value to shareholders.

Conclusion

Amgen's third-quarter results underscore its commitment to innovation, sustained market performance, and growing demand for its products. With a strong pipeline and a strategy geared towards long-term success, Amgen remains poised to make significant strides in the biotechnology sector, benefiting both patients and investors alike. As the company prepares for future challenges and opportunities, the commitment to enhancing patient care and improving health outcomes continues to be at the forefront of its mission.